# Field Trial of PfSPZ-LARC2 Vaccine in Burkinabe Adults

> **NCT07385287** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Sanaria Inc.** · enrollment: 180 (estimated)

## Conditions studied

- Malaria (Plasmodium Falciparum)

## Interventions

- **BIOLOGICAL:** Genetically attenuated PfSPZ Vaccine
- **OTHER:** Normal Saline (0.9% Sodium Chloride)

## Key facts

- **NCT ID:** NCT07385287
- **Lead sponsor:** Sanaria Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-04
- **Primary completion:** 2026-12
- **Final completion:** 2027-02
- **Target enrollment:** 180 (ESTIMATED)
- **Last updated:** 2026-02-19

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07385287

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07385287, "Field Trial of PfSPZ-LARC2 Vaccine in Burkinabe Adults". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07385287. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*